Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-03-2022 | EMA | News

approvalsWatch

EMA supports use of relugolix for prostate cancer

Author: Hannah Kitt

print
PRINT
insite
SEARCH

medwireNews: The EMA has recommended approval of relugolix for the treatment of advanced hormone-sensitive prostate cancer.

The positive opinion follows US FDA approval of relugolix in December 2020. Both decisions are based on findings from the phase 3 HERO trial in which the gonadotropin-releasing hormone antagonist achieved a medical castration rate of 96.7% in this patient population, which was superior to the rate of 88.8% with leuprolide acetate.

Relugolix will be available as 120 mg tablets.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

23-12-2020 | FDA | News

FDA announces breast, lung, prostate cancer approvals

02-06-2020 | ASCO 2020 | News

Relugolix may offer better testosterone suppression than leuprolide
Image Credits